Senti Biosciences is trading 8.81% up at $0.47 after biotech stocks rallied broadly on positive Moderna-Merck Phase 3 personalized cancer-vaccine results.
- No clearly reported company-specific catalyst was identified for August 19, 2026.
- Investor attention may also be building ahead of the August 20, 2026 Q2 earnings discussion, but that timing does not establish causation.
- XBI was up 3.73%, supporting a sector-led explanation.